Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity

Jennifer Chu; Santiago Ramon y. Cajal; Nahum Sonenberg; Jerry Pelletier

doi:10.1016/j.gde.2017.11.002

Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity

Jennifer Chu, Santiago Ramon y. Cajal, Nahum Sonenberg, Jerry Pelletier

Departament de Ciències Morfològiques

Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts

9 Cites (Scopus)

Resum

© 2017 Elsevier Ltd There is enormous diversity in the genetic makeup and gene expression profiles between and within tumors. This heterogeneity leads to phenotypic variation and is a major mechanism of resistance to molecular targeted therapies. Here we describe a conceptual framework for targeting eukaryotic initiation factor (eIF) 4F in cancer — an essential complex that drives and promotes multiple Cancer Hallmarks. The unique nature of eIF4F and its druggability bypasses several of the heterogeneity issues that plague molecular targeted drugs developed for cancer therapy.

Idioma original	Anglès
Pàgines (de-a)	89-96
Revista	Current Opinion in Genetics and Development
Volum	48
DOIs	https://doi.org/10.1016/j.gde.2017.11.002
Estat de la publicació	Publicada - 1 de febr. 2018

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1016/j.gde.2017.11.002

Com citar-ho

@article{7ea68a48b708434cb31084696993785e,

title = "Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity",

abstract = "{\textcopyright} 2017 Elsevier Ltd There is enormous diversity in the genetic makeup and gene expression profiles between and within tumors. This heterogeneity leads to phenotypic variation and is a major mechanism of resistance to molecular targeted therapies. Here we describe a conceptual framework for targeting eukaryotic initiation factor (eIF) 4F in cancer — an essential complex that drives and promotes multiple Cancer Hallmarks. The unique nature of eIF4F and its druggability bypasses several of the heterogeneity issues that plague molecular targeted drugs developed for cancer therapy.",

author = "Jennifer Chu and Cajal, {Santiago Ramon y.} and Nahum Sonenberg and Jerry Pelletier",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/j.gde.2017.11.002",

language = "English",

volume = "48",

pages = "89--96",

journal = "Current Opinion in Genetics and Development",

issn = "0959-437X",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity

AU - Chu, Jennifer

AU - Cajal, Santiago Ramon y.

AU - Sonenberg, Nahum

AU - Pelletier, Jerry

PY - 2018/2/1

Y1 - 2018/2/1

N2 - © 2017 Elsevier Ltd There is enormous diversity in the genetic makeup and gene expression profiles between and within tumors. This heterogeneity leads to phenotypic variation and is a major mechanism of resistance to molecular targeted therapies. Here we describe a conceptual framework for targeting eukaryotic initiation factor (eIF) 4F in cancer — an essential complex that drives and promotes multiple Cancer Hallmarks. The unique nature of eIF4F and its druggability bypasses several of the heterogeneity issues that plague molecular targeted drugs developed for cancer therapy.

AB - © 2017 Elsevier Ltd There is enormous diversity in the genetic makeup and gene expression profiles between and within tumors. This heterogeneity leads to phenotypic variation and is a major mechanism of resistance to molecular targeted therapies. Here we describe a conceptual framework for targeting eukaryotic initiation factor (eIF) 4F in cancer — an essential complex that drives and promotes multiple Cancer Hallmarks. The unique nature of eIF4F and its druggability bypasses several of the heterogeneity issues that plague molecular targeted drugs developed for cancer therapy.

U2 - 10.1016/j.gde.2017.11.002

DO - 10.1016/j.gde.2017.11.002

M3 - Review article

C2 - 29169064

SN - 0959-437X

VL - 48

SP - 89

EP - 96

JO - Current Opinion in Genetics and Development

JF - Current Opinion in Genetics and Development

ER -

Eukaryotic initiation factor 4F — sidestepping resistance mechanisms arising from expression heterogeneity

Resum

SDG de les Nacions Unides

Accés al document

Fingerprint

Com citar-ho